tak-875 Search Results


tak875  (MedChemExpress)
93
MedChemExpress tak875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak875, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak875/product/MedChemExpress
Average 93 stars, based on 1 article reviews
tak875 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
tak-875  (Takeda)
90
Takeda tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak 875, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak-875/product/Takeda
Average 90 stars, based on 1 article reviews
tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
etc inhibition induced by tak-875  (DILIsym Services Inc)
90
DILIsym Services Inc etc inhibition induced by tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Etc Inhibition Induced By Tak 875, supplied by DILIsym Services Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/etc inhibition induced by tak-875/product/DILIsym Services Inc
Average 90 stars, based on 1 article reviews
etc inhibition induced by tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tak-875  (Celon Pharma)
90
Celon Pharma tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak 875, supplied by Celon Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak-875/product/Celon Pharma
Average 90 stars, based on 1 article reviews
tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
3 h]‑tak‑875  (Quotient Bioresearch)
90
Quotient Bioresearch 3 h]‑tak‑875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
3 H]‑Tak‑875, supplied by Quotient Bioresearch, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3 h]‑tak‑875/product/Quotient Bioresearch
Average 90 stars, based on 1 article reviews
3 h]‑tak‑875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tak875  (Cayman Chemical)
90
Cayman Chemical tak875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak875, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak875/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
tak875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tak-875  (ChemScene llc)
90
ChemScene llc tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak 875, supplied by ChemScene llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak-875/product/ChemScene llc
Average 90 stars, based on 1 article reviews
tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
3h-tak-875  (American Radiolabeled Chemicals Inc)
90
American Radiolabeled Chemicals Inc 3h-tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
3h Tak 875, supplied by American Radiolabeled Chemicals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3h-tak-875/product/American Radiolabeled Chemicals Inc
Average 90 stars, based on 1 article reviews
3h-tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tak875 a11018  (Adooq Bioscience LLC)
90
Adooq Bioscience LLC tak875 a11018
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak875 A11018, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak875 a11018/product/Adooq Bioscience LLC
Average 90 stars, based on 1 article reviews
tak875 a11018 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ffa1 agonist, tak-875 (at 30 nm, 300 nm or 3 μm)  (Merck & Co)
90
Merck & Co ffa1 agonist, tak-875 (at 30 nm, 300 nm or 3 μm)
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Ffa1 Agonist, Tak 875 (At 30 Nm, 300 Nm Or 3 μm), supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ffa1 agonist, tak-875 (at 30 nm, 300 nm or 3 μm)/product/Merck & Co
Average 90 stars, based on 1 article reviews
ffa1 agonist, tak-875 (at 30 nm, 300 nm or 3 μm) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tak-875  (Boehringer Ingelheim)
90
Boehringer Ingelheim tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak 875, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak-875/product/Boehringer Ingelheim
Average 90 stars, based on 1 article reviews
tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tak-875  (Sanofi)
90
Sanofi tak-875
DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM <t>TAK875.</t> (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).
Tak 875, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tak-875/product/Sanofi
Average 90 stars, based on 1 article reviews
tak-875 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM TAK875. (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).

Journal: RSC Advances

Article Title: Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products

doi: 10.1039/c9ra02142f

Figure Lengend Snippet: DMR response of ligands on CHO-FFA4 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TUG891, 10 μM GSK137647A, 12.5 μM GW9508 and 10 μM TAK875. (B) Real-time DMR of 25 μM ALA after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of ALA at indicated concentrations on the parental cell line CHO-K1. (D) Real-time DMR response of 0.5 μM GSK137647A after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR response of 0.5 μM TUG891 after CHO-FFA4 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of GSK137647A at indicated concentrations on CHO-K1 cells. (G) Real-time DMR of 25 μM GW9508 on CHO-FFA4 cells after cells pretreated with AH7614 at indicated concentrations. (H) Amplitudes as a function of each agonist doses. (I) The concentration-dependent inhibition of the 0.5 μM TUG891 by GW9508, GSK137647A, TUG891 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).

Article Snippet: TAK875 and GW1100 were purchased from MedChem Express (USA).

Techniques: Concentration Assay, Inhibition

Potency values (EC 50 and IC 50 ) of agonists in CHO-FFA4, CHO-FFA1 and HT29 cells

Journal: RSC Advances

Article Title: Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products

doi: 10.1039/c9ra02142f

Figure Lengend Snippet: Potency values (EC 50 and IC 50 ) of agonists in CHO-FFA4, CHO-FFA1 and HT29 cells

Article Snippet: TAK875 and GW1100 were purchased from MedChem Express (USA).

Techniques:

DMR response of ligands in CHO-FFA1 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TAK875, 10 μM GW9508, 25 μM TUG891 and 100 μM GSK137647A. (B) Real-time DMR of 30 μM ALA after CHO-FFA1 cells pretreated with GW1100 at indicated concentrations. (C–E) Real-time DMR response of agonists (0.5 μM TAK875, 1 μM GW9508 and 30 μM TUG891) after cells pretreated with GW1100 at indicated concentrations. (F) Amplitudes as a function of each agonist doses. (G) The concentration-dependent inhibition of the 1 μM GW9508 DMR by TAK875, GW9508, TUG891 and ALA. (H) Amplitudes as a function of MEDICA16 and ALA doses. (I) Real-time DMR response of 25 μM MEDICA16 after cells pretreated with GW1100 at indicated concentrations. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).

Journal: RSC Advances

Article Title: Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products

doi: 10.1039/c9ra02142f

Figure Lengend Snippet: DMR response of ligands in CHO-FFA1 cells. (A) Real-time DMR response of 100 μM ALA, 10 μM TAK875, 10 μM GW9508, 25 μM TUG891 and 100 μM GSK137647A. (B) Real-time DMR of 30 μM ALA after CHO-FFA1 cells pretreated with GW1100 at indicated concentrations. (C–E) Real-time DMR response of agonists (0.5 μM TAK875, 1 μM GW9508 and 30 μM TUG891) after cells pretreated with GW1100 at indicated concentrations. (F) Amplitudes as a function of each agonist doses. (G) The concentration-dependent inhibition of the 1 μM GW9508 DMR by TAK875, GW9508, TUG891 and ALA. (H) Amplitudes as a function of MEDICA16 and ALA doses. (I) Real-time DMR response of 25 μM MEDICA16 after cells pretreated with GW1100 at indicated concentrations. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).

Article Snippet: TAK875 and GW1100 were purchased from MedChem Express (USA).

Techniques: Concentration Assay, Inhibition

DMR response of ligands in HT29 cells. (A) Real-time DMR response of 100 μM ALA, 4 μM TUG891, 16.7 μM GSK137647A, 10 μM TAK875 and 11.1 μM GW9508. (B) Real-time DMR of 60 μM ALA after HT29 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of 60 μM ALA after HT29 cells pretreated with GW1100 at indicated concentrations. (D) Real-time DMR of 2 μM TUG891 after HT29 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR of 16 μM GSK137647A after HT29 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of 2 μM TUG891 after HT29 cells pretreated with GW1100 at indicated concentrations. (G) Real-time DMR of 16 μM GW9508 after HT29 cells pretreated with AH7614 at indicated concentrations. (H) Real-time DMR of 16 μM GW9508 after HT29 cells pretreated with GW1100 at indicated concentrations. (I) Real-time DMR of 50 μM MEDICA16 after HT29 cells pretreated with GW1100 at indicated concentrations. (J) Amplitudes as a function of each agonist doses. (K) The concentration-dependent inhibition of the 5 μM TUG891 DMR by TUG891, GSK137647A, GW9508 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).

Journal: RSC Advances

Article Title: Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products

doi: 10.1039/c9ra02142f

Figure Lengend Snippet: DMR response of ligands in HT29 cells. (A) Real-time DMR response of 100 μM ALA, 4 μM TUG891, 16.7 μM GSK137647A, 10 μM TAK875 and 11.1 μM GW9508. (B) Real-time DMR of 60 μM ALA after HT29 cells pretreated with AH7614 at indicated concentrations. (C) Real-time DMR of 60 μM ALA after HT29 cells pretreated with GW1100 at indicated concentrations. (D) Real-time DMR of 2 μM TUG891 after HT29 cells pretreated with AH7614 at indicated concentrations. (E) Real-time DMR of 16 μM GSK137647A after HT29 cells pretreated with AH7614 at indicated concentrations. (F) Real-time DMR of 2 μM TUG891 after HT29 cells pretreated with GW1100 at indicated concentrations. (G) Real-time DMR of 16 μM GW9508 after HT29 cells pretreated with AH7614 at indicated concentrations. (H) Real-time DMR of 16 μM GW9508 after HT29 cells pretreated with GW1100 at indicated concentrations. (I) Real-time DMR of 50 μM MEDICA16 after HT29 cells pretreated with GW1100 at indicated concentrations. (J) Amplitudes as a function of each agonist doses. (K) The concentration-dependent inhibition of the 5 μM TUG891 DMR by TUG891, GSK137647A, GW9508 and ALA. All data represent mean ± s.d. from three independent measurements, each in duplicate ( n = 6).

Article Snippet: TAK875 and GW1100 were purchased from MedChem Express (USA).

Techniques: Concentration Assay, Inhibition